参考文献/References:
[1] 王维威,张家齐,李单青.小细胞肺癌的免疫治疗临床进展[J].中国肺癌杂志,2022,25(6):425-433.
[2] Rudin CM,Giaccone G,Ismaila N.Treatment of small-cell lung cancer:American society of clinical oncology endorsement of the american college of chest physicians guideline[J].J Oncol Pract,2016,12(1):83-86.
[3] Früh M,De Ruysscher D,Popat S,et al.ESMO guidelines working group.Small-cell lung cancer(SCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2013,24:23813929.
[4] Artal-Cortés A,Dómine-Gómez M,Font-Pous A,et al.SEOM clinical guidelines for the treatment of small-cell lung cancer[J].Clin Transl Oncol,2010,12(1):27-31.
[5] Van-Allen EM,Miao D,Schilling B,et al.Genomic correlates of response to CTLA-4 blockade in metastatic melanoma[J].Science,2015,350(6257):207-211.
[6] Gaillard H,García-Muse T,Aguilera A.Replication stress and cancer[J].Nat Rev Cancer,2015,15(5):276-289.
[7] Hanel W,Moll UM.Links between mutant p53 and genomic instability[J].J Cell Biochem,2012,113(2):433-439.
[8] Alexandrov LB,Nik-Zainal S,Wedge DC,et al.Signatures of mutational processes in human cancer[J].Nature,2013,500(7463):415-421.
[9] 岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495-498,502.
[10] Zhao X,Kallakury B,Chahine JJ,et al.Surgical resection of SCLC:Prognostic factors and the tumor microenvironment[J].J Thorac Oncol,2019,14(5):914-923.
[11] Zhao X,Kallakury B,Chahine JJ,et al.Surgical resection of SCLC:Prognostic factors and the tumor microenvironment[J].J Thorac Oncol,2019,14(5):914-923.
[12] Chen L,Flies DB.Molecular mechanisms of T cell co-stimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242.
[13] Keir ME,Butte MJ,Freeman GJ,et al.PD-1 and its ligands in tolerance and immunity[J].Annu Rev Immunol,2008,26:677-704.
[14] Reck M,Bondarenko I,Luft A,et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer:Results from a randomized,double-blind,multicenter phase 2 trial[J].Ann Oncol,2013,24(1):75-83.
[15] Reck M,Luft A,Szczesna A,et al.Phase Ⅲ randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer[J].J Clin Oncol,2016,34(31):3740-3748.
[16] Gadgeel SM,Pennell NA,Fidler MJ,et al.Phase Ⅱ study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer(SCLC)[J].J Thorac Oncol,2018,13(9):1393-1399.
[17] Owonikoko TK,Park K,Govindan R,et al.Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer:Checkmate 451[J].J Clin Oncol,2021,39(12):1349-1359.
[18] Ready N,Farago AF,de Braud F,et al.Third-line nivolumab monotherapy in recurrent SCLC:Checkmate 032[J].J Thorac Oncol,2019,14(2):237-244.
[19] Spigel DR,Vicente D,Ciuleanu TE,et al.Second-line nivolumab in relapsed small-cell lung cancer:Checkmate 331 [J].Ann Oncol,2021,32(5):631-641.
[20] Crossland DL,Denning WL,Ang S,et al.Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models[J].Oncogene,2018,37(27):3686-3697.
[21] Weihrauch MR,Richly H,Von Bergwelt-Baildon MS,et al.Phase Ⅰ clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours[J].Eur J Cancer,2015,51(2):146-56.
[22] 刘振宇,王宏伟.小鼠原位肺癌模型构建及在放射治疗研究中的意义[J].陕西医学杂志,2022,51(7):791-794,810.